CAR-T Meeting 2024 | The effect of lymphodepleting agents on rate and severity of toxicities following CAR-T infusion
In this video, Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, outlines the three major toxicities associated with CAR T-cell therapy and comments on how the choice of agents during lymphodepletion may influence the rates and severity of these toxicities. Fludarabine/cyclophosphamide (Flu/Cy) lymphodepletion increases in efficacy as the dose of the chemotherapy is increased; however, this also leads to more significant toxicity. Increasing evidence has shown that lymphodepletion using bendamustine is equally efficacious, with lower levels of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and long-term cytopenias (as a result of faster neutrophil recovery). This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
